DSM looking at options to exit its caprolactam business
11:43 AM MDT | July 3, 2013
DSM today declined to comment on a Bloomberg report that it is considering exiting the caprolactam business. However, it confirmed previously announced plans to reduce its exposure to the merchant caprolactam market. â€śDSM is considering various options and has nothing new to report to its previous public statements,â€ť the company said. DSM is among the worldâ€™s largest merchant sellers of caprolactam, with about 60% of its production at Geelen, Netherlands, and Augusta, GA, being sold to third parties. In addition, a joint venture with Sinopec is building a...
Access is for Chemweek 24/7 PLUS Members ONLY
This information is only available to Chemweek 24/7 PLUS members who have subscribed to Chemweek’s Business Daily. If you are a member, please log in, OR if you have a trial membership, please use your trial membership account information.
Forgot your user ID or password? Click here to have it sent to you.